"In both the Pfizer-BioNTech and Moderna Phase 3 trials, the first dose achieved at least 89 percent efficacy starting two weeks after immunization. Preliminary data from Israel’s mass inoculation campaign suggest likewise, with significant protection against infection reported in the first 430,000 individuals who received an initial shot."
Užsisakykite:
Rašyti komentarus (Atom)
Komentarų nėra:
Rašyti komentarą